Chapel Hill, NC, United States of America

Balasingam Radhakrishnan

This inventor holds 38 USPTO granted patents and 5 published patent applications, plus 5 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Biocon Limited, Cidara Therapeutics, Inc., Resq Pharmaceuticals LLC. Active years: 2001-2026.

USPTO Granted Patents = 38 

% Patents Active = 76.3

 

 

Average Co-Inventor Count = 4.4

ph-index = 10

Forward Citations = 277(Granted Patents)


Company Filing History:


Years Active: 2001-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antifungal Agents
Insulin Conjugates
Edema Treatments
Echinocandin Compounds
Dosing Regimens
Fatty Acid Formulations
Therapeutic Agents
Drug-Oligomer Conjugates
Natriuretic Compounds
Microemulsion Formulations
Polypeptide Conjugates
Pharmaceutical Compositions
38 patents (USPTO):Explore Patents

Title: The Innovative Journey of Balasingam Radhakrishnan

Introduction: Balasingam Radhakrishnan, a pioneering inventor based in Chapel Hill, NC, has made significant contributions to the field of technology through his groundbreaking innovations.

Latest Patents: Balasingam Radhakrishnan's most recent patents focus on advancements in artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a career spanning over two decades, Balasingam Radhakrishnan has established himself as a leading figure in the tech industry, holding multiple patents that have revolutionized various sectors.

Collaborations: Throughout his career, Balasingam Radhakrishnan has collaborated with top research institutions, universities, and tech companies to further develop his inventions and bring them to the market, solidifying his reputation as a visionary inventor.

Conclusion: Balasingam Radhakrishnan's relentless pursuit of innovation and his dedication to creating cutting-edge technologies have cemented his legacy as a trailblazer in the world of inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…